Decitabine

Name: Decitabine
Brand: Selleck Chemicals
SKU: S1200
Rating: 5 (58 reviews)

For research use only. Not for use in humans.

Catalog No.S1200 Synonyms: Deoxycytidine

58 publications

Molecular Weight(MW): 228.21

Decitabine is a DNA methyltransferase inhibitor, incorporating into DNA and resulting in hypomethylation of DNA and intra-S-phase arrest of DNA replication. It is used to treat myelodysplastic syndrome (MDS).

Selleck's Decitabine has been cited by 58 publications

Nat Biotechnol, 2019, 10.1038/s41587-019-0372-z

PubMed: 31873215 ( click the link to review the publication )

Nat Med, 2019, 25(7):1073-1081

PubMed: 31270502 ( click the link to review the publication )

Cancer Discov, 2019, 9(1):34-45

PubMed: 30297358 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell Metab, 2019, 29(4):886-900

PubMed: 30661930 ( click the link to review the publication )

Cancer Cell, 2018, 34(6):906-921

PubMed: 30537513 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(13):4155-4167

PubMed: 30952643 ( click the link to review the publication )

Theranostics, 2019, 9(9):2424-2438

PubMed: 31131045 ( click the link to review the publication )

Theranostics, 2019, 9(21):6175-6190

PubMed: 31534544 ( click the link to review the publication )

Cancer Res, 2019, 79(10):2761-2774

PubMed: 30877105 ( click the link to review the publication )

Cell Rep, 2019, 27(11):3331-3344

PubMed: 31189115 ( click the link to review the publication )

Cell Death Differ, 2019, 26(5):843-859

PubMed: 29988076 ( click the link to review the publication )

J Nucl Med, 2019, 10.2967/jnumed.118.224048

PubMed: 30796167 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 10.1111/pcmr.12849

PubMed: 31758842 ( click the link to review the publication )

Signal Transduct Target Ther, 2019, 4:51

PubMed: 31815008 ( click the link to review the publication )

ACS Chem Biol, 2019, 14(3):348-355

PubMed: 30763062 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(8):14040-14049

PubMed: 30623427 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

Biomed Pharmacother, 2019, 112:108699

PubMed: 30970511 ( click the link to review the publication )

Front Genet, 2019, 10:422

PubMed: 31130994 ( click the link to review the publication )

BMC Cancer, 2019, 19(1):202

PubMed: 30841886 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 10.1016/j.bbrc.2019.06.097

PubMed: 31277942 ( click the link to review the publication )
Mol Biol Rep, 2019, 10.1007/s11033-019-04892-7

PubMed: 31147860 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16970

PubMed: 31740746 ( click the link to review the publication )

J Clin Invest, 2018, 128(1):446-462

PubMed: 29202477 ( click the link to review the publication )

Nat Commun, 2018, 9(1):3164

PubMed: 30089774 ( click the link to review the publication )

Leukemia, 2018, 32(4):900-910

PubMed: 29249821 ( click the link to review the publication )

Theranostics, 2018, 8(16):4520-4534

PubMed: 30214636 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):62

PubMed: 29728108 ( click the link to review the publication )

Oncoimmunology, 2018, 7(10):e1484981

PubMed: 30288346 ( click the link to review the publication )

J Gastroenterol, 2018, 53(1):71-83

PubMed: 28315004 ( click the link to review the publication )

Oncogenesis, 2018, 7(11):91

PubMed: 30467308 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(4):696-706

PubMed: 29453320 ( click the link to review the publication )

Antimicrob Agents Chemother, 2018, 62(9)

PubMed: 29914957 ( click the link to review the publication )

Cancer Immunol Immunother, 2018, 67(2):237-246

PubMed: 29058035 ( click the link to review the publication )

Biomed Pharmacother, 2018, 104:204-210

PubMed: 29772441 ( click the link to review the publication )

Leuk Res, 2018, 64:34-41

PubMed: 29175379 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2304-2314

PubMed: 28729399 ( click the link to review the publication )

Br J Haematol, 2017, 10.1111/bjh.14707

PubMed: 28439875 ( click the link to review the publication )

J Biol Chem, 2017, 292(31):12842-12859

PubMed: 28634230 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2017, 143(11):2189-2200

PubMed: 28730284 ( click the link to review the publication )

Am J Transl Res, 2017, 9(2):454-465

PubMed: 28337274 ( click the link to review the publication )

Alcohol, 2017, 60:95-101

PubMed: 28433417 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56802-56815

PubMed: 28915632 ( click the link to review the publication )

Oncotarget, 2017, 8(51):89182-89193

PubMed: 29179510 ( click the link to review the publication )

Nat Commun, 2016, 7:11040

PubMed: 27010513 ( click the link to review the publication )
Mol Cell Biochem, 2016, 415(1-2):197-205

PubMed: 27000860 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(7):1628-38

PubMed: 25623213 ( click the link to review the publication )

Cancer Res, 2015, 75(15):2987-98

PubMed: 26122843 ( click the link to review the publication )

J Immunol, 2015, 10.4049/jimmunol.1403196

PubMed: 25825452 ( click the link to review the publication )

Cell Cycle, 2015, 10.1080/15384101.2015.1044174

PubMed: 25946202 ( click the link to review the publication )

Oncol Lett, 2015, 9(4):1691-1698

PubMed: 25789025 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(22):4143-64

PubMed: 25202123 ( click the link to review the publication )

PLoS One, 2014, 9(5):e97719

PubMed: 24874286 ( click the link to review the publication )

Exp Hematol, 2014, 42(7):536-46

PubMed: 24704162 ( click the link to review the publication )

Leuk Res, 2014, 38(3):402-10

PubMed: 24484870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Description

Targets

DNA methylation ^[1]
(HL-60, KG1a cells)

In vitro

Decitabine inhibits cell growth in a dose and time-dependent manner with IC50 of approximately 438 nM and 43.8 nM for 72 hours and 96 hours exposure in HL-60 and KG1a leukemic cells, respectively. ^[1] A recent study shows that Decitabine exhibits high anti-proliferative and pro-apoptotic activity against anaplastic large cell lymphoma (ALCL), and inhibits [³H]–thymidine uptake in KARPAS-299 cells with EC50 of 0.49 μM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Eca109	M4nkS2Z2dmO2aX;uJGF{e2G7	MnXFNE42yqEQvF2=	NV[3TGo{OjRiaB?=	MXH3ZZRmeg>?	NIPnUmZud2S3bHH0[ZMhfGinIHflcoUh\XiycnXzd4lwdiCxZjDNRWdGNUFibXXtZoVzew>?	M{PDbFI2OTJ\|MEiy
Eca109	NYTX[FAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4X5bVAvPS9{LkWvOUDPxE1?	NV;rfmFNOjRxNEivO\|IhcA>?	M2nvfJdifGW{	NF;CdJRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	Mk[4NlUyOjNyOEK=
Eca109	MW\GeY5kfGmxbjDBd5NigQ>?	NHyzZmMxNjYEoN88US=>	Mnu0Ok8yOi9{NDDo	MYn3ZZRmeg>?	Ml:zbY5pcWKrdIOgZ4VtdCCvaXfyZZRqd28EoB?=	Mli1NlUyOjNyOEK=
Eca109	Mlq0SpVv[3Srb36gRZN{[Xl?	NHi1SmExNjYEoN88US=>	NE\jXmgzPCCq	M2TOdJdifGW{	MWDpcohq[mm2czDj[YxtKGmwdnHzbY9v	MkC0NlUyOjNyOEK=
Eca109	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnnNNE42yqEQvF2=	Ml7jNlQhcA>?	NHzVS2x4[XSnch?=	NUW3[nhKcW6mdXPld{BIOi:PIHHydoV{fCCrbjD0bIUh[2WubDDjfYNt\Q>?	NFTw[ZYzPTF{M{C4Ni=>
Eca109	MmfpSpVv[3Srb36gRZN{[Xl?	MojONE42NzFizszN	NWnvRY02OjRiaB?=	M{HtSZdifGW{	NFvEN5Nl\WO{ZXHz[ZMh\XiycnXzd4lwdiCxZjDOSk3PwkJ{IHHu[EBOVVB{	Mn3uNlUyOjNyOEK=
SW1116	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2jV[VAvPS9zL{KvOUDPxE1?	NV:5NZdGPDhiaB?=	MlzwSG1UVw>?	M4PTR4VvcGGwY3XzJJRp\SCJZX\peIlvcWJiaX7keYNm\CClZXzsJIlvcGmkaYTpc44>	NIG4SYYzPDh5NEK4Oi=>
LOVO	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWLiS\|ViOC53L{GvNk82KM7:TR?=	M1W1PFQ5KGh?	M{Pzb2ROW09?	NXixcmZJ\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>?	M1W3[lI1QDd2Mki2
SW1116	MWjGeY5kfGmxbjDBd5NigQ>?	MlrKNVAh\|ryP	MVe0PEBp	MVPEUXNQ	M3izZYlv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>?	M2fE[FI1QDd2Mki2
LOVO	NVXVN45FTnWwY4Tpc44hSXO\|YYm=	NUXpWZZOOTBizszN	Mof1OFghcA>?	MVTEUXNQ	M3PJeolv[3KnYYPld{B1cGViZX\m[YN1cX[nIHH0JIlvcGmkaYTpcochSUuWIHHu[EBuXE:UIIPp[45idGmwZzDwZZRpf2G7czDjc41jcW6nZDD3bZRpKGenZnn0bY5q[g>?	MUGyOFg4PDJ6Nh?=
SW1116	NIrSfYdCeG:ydH;zbZMhSXO\|YYm=	M{\ORVExKM7:TR?=	NYrkRVB4PDhiaB?=	NXuyVnB3TE2VTx?=	M1L6RYVvcGGwY3XzJGdm\mm2aX7pZk1qdmS3Y3XkJIFxd3C2b4Ppdy=>	MlvxNlQ5PzR{OE[=
LOVO	MWPBdI9xfG:\|aYOgRZN{[Xl?	MnHTNVAh\|ryP	NVraZm8zPDhiaB?=	NF:2cZhFVVOR	MWnlcohidmOnczDH[YZqfGmwaXKtbY5lfWOnZDDhdI9xfG:\|aYO=	M1;zb\|I1QDd2Mki2
RPMI-8226	MoHjRZBweHSxc3nzJGF{e2G7	MofqNU8zKM7:TR?=	NH25bII1QC95Mj:5OkBp	NVe3R3ZWTE2VTx?=	MYPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	M{HEXlI1QDN\|MUC4
OPM-2	M2jZbGFxd3C2b4Ppd{BCe3OjeR?=	MUCxM\|Ih\|ryP	NXLYOGFsPzJxOU[vNVIxKGh?	MU\EUXNQ	NW[wdHh1cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MX2yOFg{OzFyOB?=
JJN3	M4q3R2Fxd3C2b4Ppd{BCe3OjeR?=	NIjScpkxNjVxMTFOwG0>	MkHmNlQwPDhiaB?=	NXPBNmhkTE2VTx?=	MkHBbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NGTCS5YzPDh\|M{GwPC=>
NCI-H929	NWn5eYhtSXCxcITvd4l{KEG\|c3H5	MVOxM\|Ih\|ryP	NH\MflQ4Oi97Nj:xNlAhcA>?	NUnlcXBGTE2VTx?=	NXLRe2ZNcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NYXGbolqOjR6M{OxNFg>
RPMI-8226	NWr0[ZdbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUexM\|Ih\|ryP	NWDXPHZzOjRxNEivO\|IhcA>?	MXvEUXNQ	MV7h[oZm[3S\|IHPlcIwh[3mlbHWgdJJw\3Knc4Ppc44hdmWpYYTpeoVtgQ>?	NIXUeZczPDh\|M{GwPC=>
OPM-2	MoD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXOxM\|Ih\|ryP	MX:yOE81QC95MjDo	M1PWfWROW09?	NF7kOmVi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?=	MVyyOFg{OzFyOB?=
JJN3	MmrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVGwMlUwOSEQvF2=	MnK1NlQwPDhxN{KgbC=>	NFnuRW9FVVOR	NVjWWZN4[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm=	MkHYNlQ5OzNzMEi=
NCI-H929	NGm5empIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml3nNU8zKM7:TR?=	MUSyOE81QC95MjDo	MY\EUXNQ	MoPaZYZn\WO2czDj[YxtKGO7Y3zlJJBzd2e{ZYPzbY9vKG6nZ3H0bZZmdHl?	NFjRe5ozPDh\|M{GwPC=>
HeLa	MmHTT4lv[XOnIFHzd4F6				MXzLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx	NELkWpAzPDd6MEC5PC=>
HeLa	MYHLbY5ie2ViQYPzZZk>				M2G3TmtqRTVwNjFCtUAxNjVizszNJIZweiCqRV7UNi=>	MV2yOFc5ODB7OB?=
HeLa	NXHIeXVCU2mwYYPlJGF{e2G7				M2fFT2tqRTJzLk[gxtEhOy5yIN88UUBnd3JiaFPOWFE>	MVKyOFc5ODB7OB?=
HeLa	M3HyeWtqdmG\|ZTDBd5NigQ>?				NF:zPINMcT1zND60JOKyKDRwNjFOwG0h\m:{IHjDUnQ{	NWWxZoJbOjR5OECwPVg>
NB4	M1vv[WZ2dmO2aX;uJGF{e2G7	MVKyMlUwPS95LkWvNVAh\|ryP	NIi5U\|YzPCCq	NHvBTpNFVVOR	MkPkbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=>	M3rS[FI1PDh2OEew
CD4+ CD25− T	NFrq[YxHfW6ldHnvckBCe3OjeR?=	NGjCVJkyNzVizszN			NXrD[Vl4emWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w	MXeyOFQ4PjN4MB?=
BV-173	MnLMRZBweHSxc3nzJGF{e2G7	MYmwMlI2NzBwNT:wMlc2NzFizszN	M{O2PFQ5Nzd{L{m2JIg>	MUhCpHBDWw>?	MoHNbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy	MonNNlQ1OjN4MUO=
ML-1	Ml;SRZBweHSxc3nzJGF{e2G7	MlvsNE4zPS9yLkWvNE44PS9zIN88US=>	M1nuNVQ5Nzd{L{m2JIg>	NHT2TmzDqFCEUx?=	MYTpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	MWeyOFQzOzZzMx?=
HL-60	NVuxSm53SXCxcITvd4l{KEG\|c3H5	MkfMNE4zPS9yLkWvNE44PS9zIN88US=>	NIrTe5A1QC95Mj:5OkBp	NF;qZ3TDqFCEUx?=	MYnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	NH[1SWIzPDR{M{[xNy=>
KG-1a	MkG1RZBweHSxc3nzJGF{e2G7	MV[wMlI2NzBwNT:wMlc2NzFizszN	MnWzOFgwPzJxOU[gbC=>	MX9CpHBDWw>?	MV\pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHLveIgh\G:\|ZT2gZY5lKHSrbXWtJIRmeGWwZHXueEBu[W6wZYK=	NUX2NG54OjR2MkO2NVM>
BV-173	MkXpSpVv[3Srb36gRZN{[Xl?	NIOyR4IzPTBxNUCwcm0>	NUTCVpBTPDhiaB?=	MVVCpHBDWw>?	NUn6NohwcW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	Mn3JNlQ1OjN4MUO=
CEM	MnXBSpVv[3Srb36gRZN{[Xl?	NX\QTGU{OjVyL{WwNI5O	M3nY[FQ5KGh?	M4rrWuKhWEKV	MWfpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	NXO2fItlOjR2MkO2NVM>
HL-60	NWjsW2oyTnWwY4Tpc44hSXO\|YYm=	NFPIXWszPTBxNUCwcm0>	M3PP[FQ5KGh?	NYnXN4RkyqCSQmO=	MWrpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	MU[yOFQzOzZzMx?=
ML-1	NXO2TGNPTnWwY4Tpc44hSXO\|YYm=	M2rRWVI2OC93MEDuUS=>	MUS0PEBp	MofBxsBRSlN?	NXS0cGNScW6mdXPld{Bl\WyjeXXkJIFv\CC\|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl	NEGyOFAzPDR{M{[xNy=>
DLD-1	NEnXUINHfW6ldHnvckBCe3OjeR?=	MUGyOVAwPTBybl2=	MXW0PEBp	NUXnRVlFyqCSQmO=	M{jUTYRwKG6xdDDpcoR2[2W\|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V?	MoT3NlQ1OjN4MUO=
HCT-116	MVLGeY5kfGmxbjDBd5NigQ>?	NV7rV3VFOjVyL{WwNI5O	MWO0PEBp	MlzvxsBRSlN?	MW\kc{Bvd3RiaX7keYNmeyCmZXzhfYVlKGGwZDDzeZN1[WmwZXSgVm9UKGmwY4LlZZNm	MljENlQ1OjN4MUO=
U937-A/E-9/14/18	NFLZdmFCeG:ydH;zbZMhSXO\|YYm=	MUmwMlAyNzBwMT:xM\|ExKM7:TR?=	NHrDUFc1QCCq		NYL1UIs2cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MXeyOFMxODR3Nh?=
HT29	M4Lze2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnuyO\|IhcA>?		M4n2UWlEPTB;MUSwNOKyOTd7IN88US=>	NXXuV5JiOjRzN{KwOlE>
SW48	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWm3NkBp		Mm\QTWM2OD1zNT6yxtE3NjJizszN	NFTrcpgzPDF5MkC2NS=>
HCT116	Mo\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MlexO\|IhcA>?		MkDMTWM2OD1zLkhCtVAvPCEQvF2=	NXv1dY11OjRzN{KwOlE>
HepG2	NIHIUZZHfW6ldHnvckBCe3OjeR?=	MV2wMlUwOSEQvF2=	Ml;DNlQhcA>?	Mn[3SG1UVw>?	M3PkW5VxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w	MWWyOFE1Pjh5NB?=
LS174T	M13zN2Z2dmO2aX;uJGF{e2G7	MmPqNE42NzFizszN	NILzboIzPCCq	NVLZfFlXTE2VTx?=	NGW5cIVt\WGmIITvJIFvKGmwY4LlZZNmKG:oIF;DWG4zKGyndnXsdy=>	NFG0fHQzPDF2Nki3OC=>
HepG2	M2Tm[GFxd3C2b4Ppd{BCe3OjeR?=	MXuxM\|ExNzFyMDFOwG0>	M3LONFch\A>?	Mn6wSG1UVw>?	MYDpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NGLDN\|kzPDF2Nki3OC=>
LS174T	Mnm2RZBweHSxc3nzJGF{e2G7	M3rVZlEwOTBxMUCwJO69VQ>?	NH\PV\|Y4KGR?	MYjEUXNQ	MoG5bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MWGyOFE1Pjh5NB?=
QBC-939	MVvBdI9xfG:\|aYOgRZN{[Xl?	M3rlSVEwOTBxMUCwJO69VQ>?	MoPkO{Bl	MVLEUXNQ	NULKemV3cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWGyOFE1Pjh5NB?=
U251	MkG4RZBweHSxc3nzJGF{e2G7	NX30UnNROS9zMD:xNFAh\|ryP	M3n0blch\A>?	NEiyRpBFVVOR	MVPpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NGjkbVMzPDF2Nki3OC=>
HL-60	M2LERmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrmXmsyKM7:TR?=	NXfEN3FNPDhiaB?=		MYTpcoNz\WG\|ZYOgS\|IueGijc3WgZ4VtdCCocnHjeIlwdg>?	NHXEVpUzPDByMEOyOC=>
MDA‑MB‑453	NYrSbpR1TnWwY4Tpc44hSXO\|YYm=	M{\STFAvOi9zIN88US=>	MUm3NkBp		MmqzZ4F2e2W\|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg	M4n3[\|I{QDR2MkK4
HCC1569	NH6ycm9HfW6ldHnvckBCe3OjeR?=	M{nqUlAvOi9zIN88US=>	M2LGbFczKGh?		MofGZ4F2e2W\|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg	MljZNlM5PDR{Mki=
BT‑474	NVWyN2ZmTnWwY4Tpc44hSXO\|YYm=	Ml3jNE4zNzFizszN	MVS3NkBp		M3TRVoNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=>	NIG5XlIzOzh2NEKyPC=>
AGS	MVLBdI9xfG:\|aYOgRZN{[Xl?	NH;KTW02NzFyL{KwM\|UxKM7:TR?=	NXnycYY6PDkEoHlCpC=>	MV;EUXNQ	NXzFS2gxcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6yqB?	MlO2NlM2QDJ5OES=
A549	Ml6yRZBweHSxc3nzJGF{e2G7	Ml7TOU8yOC9{MD:1NEDPxE1?	M1T4VlQ5yqCqwrC=	MXjEUXNQ	MkCybY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA>	M{PSXFI{PTh{N{i0
AGS	M3qzU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV63SmFyPS9zMD:yNE82OCEQvF2=	NHzKSGU1QMLiaNMg	NXvYdHpWTE2VTx?=	NH\oV3RqdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA>	M4XNclI{PTh{N{i0
Kasumi-1	MXPBdI9xfG:\|aYOgRZN{[Xl?	MVWwMlUh\|ryP	NVjFRXo1PDkEoHlCpC=>		M1XMR4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj	NXm4d5dGOjN2OUOzOFg>
OCI-AML3	MWTBdI9xfG:\|aYOgRZN{[Xl?	NInyPWgzNjVizszN	M2DjNVQ5yqCqwrC=		MoLt[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBkdy22cnXheIVlKHerdHigWIYuVlBvc3O=	NHvmNmgzOzR7M{O0PC=>
MV4-11	NIPaNIlCeG:ydH;zbZMhSXO\|YYm=	MVeyMlUh\|ryP	NXm2bmxlPDkEoHlCpC=>		M4j5doRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkh[29vdILlZZRm\CC5aYToJHRnNU6SLYPj	M{HT[\|I{PDl\|M{S4
NK	MonnR5l1d3SxeHn0fUBCe3OjeR?=	NUe3b2FCOC5yMj2yNEDPxE1?	MlXlOUBl		NYfV[21m\GWlcnXhd4V{KHSqZTDjfZRwdHm2aXOgZYN1cX[rdImgc4YhVktiY3XscJMh[XRiaX70[ZJu\WSrYYTlJINwdmOnboTyZZRqd26\|IILld5VtfGmwZzDpckBiKFVvc3jhdIVlKGSxc3ZihLNz\XOyb37z[UBkfXK4ZR?=	M2D1OlI{OzJ6MEi4
NK	NWm0V2tvSXCxcITvd4l{KEG\|c3H5	NFLhcocxNjB{LUKwJO69VQ>?	M2\HbFUh\A>?		M2H6[oRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>?	MVSyN\|MzQDB6OB?=
NK	MnXnSpVv[3Srb36gRZN{[Xl?	MXWwMlAyNTJyIN88US=>	MY[1JIQ>		MUfjZZV{\XNiaInwc41mfGi7bHH0bY9vKG:oIF7LJINmdGy\|IHnuJIEh\G:\|ZfMAl5Jme3CxboPl	MXqyN\|MzQDB6OB?=
MOLT4/DNR	NXrITHM{TnWwY4Tpc44hSXO\|YYm=	MWm1JO69VQ>?	NUDIdHVoPCCm		NGDCSHFz\WS3Y3XzJGFDS0JzIH3SUmEh\XiycnXzd4lwdg>?	M{LtXlI{ODZyNUew
Jurkat/DOX	M{X0UWZ2dmO2aX;uJGF{e2G7	NIXPU4E2KM7:TR?=	NYPqNm5yPCCm		MmfWdoVlfWOnczDBRmNDOSCvUl7BJIV5eHKnc4Ppc44>	M2K2PFI{ODZyNUew
MOLT4/DNR	NUDUSYgzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Ox[FUh\|ryP	MXO0JIQ>		NWrTTI5YemWmdXPld{B1cGViSVO1NOKhfmGudXWg[o9zKGSjdX7vdpVjcWOrbjDz[Y5{cXSrdnn0fS=>	NVjmSZMxOjNyNkC1O\|A>
Jurkat/DOX	M3jFNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUX4dXRGPSEQvF2=	MXS0JIQ>		MYry[YR2[2W\|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7	NE\LUFYzOzB4MEW3NC=>
ccRCC	NWnsXW9vSXCxcITvd4l{KEG\|c3H5	Ml\TNE4xOS1zMN88US=>	NITyNVY4OiCq	M{HP[2ROW09?	MmfwbIF{KG2rbnntZYwh\W[oZXP0JI9vKGOnbHygdJJwdGmoZYLheIlwdg>?	MXmyNlgzPjR4Nx?=
TNBC	NEfsWIZCeG:ydH;zbZMhSXO\|YYm=	M2LjR\|AvODFvMUFOwG0>	M2jUc\|czKGh?	MojrSG1UVw>?	NHqxV2pp[XNibXnubY1idCCnZn\lZ5Qhd25iY3XscEBxem:uaX\ldoF1cW:w	MYqyNlgzPjR4Nx?=
A498	M1vUPGFxd3C2b4Ppd{BCe3OjeR?=	MnTJNE4xOS1zMN88US=>	M3PObVczKGh?	Mn\LSG1UVw>?	MV\pcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	MlrRNlI5OjZ2Nke=
KIJ265T	MoP5RZBweHSxc3nzJGF{e2G7	M1XyXlAvODFvMUFOwG0>	M2HhWFczKGh?	MXHEUXNQ	NUXPcIlZcW6mdXPld{B{gW6ncnfpd5Rq[yC{ZYPwc45{\XQEoIfpeIghem:vaXTldJNqdg>?	NYDsPJRzOjJ6Mk[0Olc>
MDA-231	MmKzRZBweHSxc3nzJGF{e2G7	MknmNE4xOS1zMN88US=>	NWS5UIc4PzJiaB?=	MY\EUXNQ	MULpcoR2[2W\|IIP5coVz\2m\|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu	M3PQeFIzQDJ4NE[3
BT-20	M{HiRmFxd3C2b4Ppd{BCe3OjeR?=	MkPKNE4xOS1zMN88US=>	M2jIbVczKGh?	NWHBPYlsTE2VTx?=	Mom5bY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=>	NEfkV4EzOjh{NkS2Oy=>
U937	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGj4ZoM2NTJyIN88US=>	Mnj2NlQwPDhxN{KgbC=>		NUf4R5hncW6mdXPld{BiKGSnY4LlZZNmKGmwIHPlcIwhfmmjYnnsbZR6KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>?	M3\xU\|IzPzZ5MEKx
HL60	M1XBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;B[I9HPS1{MDFOwG0>	MYKyOE81QC95MjDo		NFzNbGdqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz	NIrBWHQzOjd4N{CyNS=>
U937	MXfBdI9xfG:\|aYOgRZN{[Xl?	NILVZWgyPSEQvF2=	NGr0XI8zPC92OD:3NkBp		NG\RRVVqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	NFvwSWczOjd4N{CyNS=>
HL60	M1rFcWFxd3C2b4Ppd{BCe3OjeR?=	M1fXcVE2KM7:TR?=	NWn6e4xsOjRxNEivO\|IhcA>?		MlmzbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	MXeyNlc3PzB{MR?=
LS411N	MXrBdI9xfG:\|aYOgRZN{[Xl?	M3zYblAvPSEQvF2=	MVG3NkBp		NUXzVppFcW6lcnXhd4V{KE[jczDtVm5CKGyndnXs	M{C3flIzPDZzNkm1
MDA-MB-231	MknFRZBweHSxc3nzJGF{e2G7	NUm1bZZTOTBizszN	M{fX[\|Q5KGh?		NGDIZVNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NFztR5EzOTh6N{[5Oy=>
MCF-7	MmHHRZBweHSxc3nzJGF{e2G7	MoLvNVAh\|ryP	NGDqZ4Y1QCCq		NWDweoZ4emWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MWCyNVg5PzZ7Nx?=
A375	MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MX2wMlUh\|ryP	MoW2NU82NzhiZB?=		M2TCcolvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	MUOyNVc6PjZ{Mh?=
SKMEL1	NWfLNHFmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2CwWFAvPSEQvF2=	NVrDXodqOS93L{ig[C=>		Ml60bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCjbnSgbY5lfWOnczDkbYZn\XKnboTpZZRqd25ib3[gcYVt[W6xbXGgZ4VtdHN?	Mn[4NlE4QTZ4MkK=
SKMEL3	NXSy[nhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jtbVAvPSEQvF2=	NHXib3MyNzVxODDk		NH;Jd\|dqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?=	NVL5eoR[OjF5OU[2NlI>
SKMEL28	NETremNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnO1NE42KM7:TR?=	M1zue\|EwPS96IHS=		NY\TeHFbcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	MUWyNVc6PjZ{Mh?=
MeWo	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3vsT\|AvPSEQvF2=	M4LR[FEwPS96IHS=		M13Bd4lvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy\|	NUX4UFNMOjF5OU[2NlI>
B16	M1jieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mly5NE42KM7:TR?=	NH[yWY4yNzVxODDk		NYTSNIw2cW6qaXLpeJMheHKxbHnm[ZJifGmxbjDhcoQhcW6mdXPld{BlcW[oZYLlcpRq[XSrb36gc4YhdWWuYX7vcYEh[2WubIO=	NVHrXYFJOjF5OU[2NlI>
Ly 1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mkn1NlQhcA>?		NWjiUmt[UUN3ME23MlMh\|ryP	NYPSS4VuOjF5N{KwOFk>
Ly 7	NGTlRpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnzQNlQhcA>?		Mkn6TWM2OD1zMD63JO69VQ>?	NVLKXIN2OjF5N{KwOFk>
Su-DHL6	MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NIC2O5UzPCCq		MoXmTWM2OO,:nkKwJO69VQ>?	NULNNYg1OjF5N{KwOFk>
Ly 10	MmTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1HkbVI1KGh?		NXruNJZSUUN3MP-8olIxKM7:TR?=	NHvC[lgzOTd5MkC0PS=>
RIVA	MkDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MUeyOEBp		MWDJR\|Ux97zgMkCg{txO	MVWyNVc4OjB2OR?=
Su-DHL2	NGrWe5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYTiZoYxOjRiaB?=		NFfPNWFKSzVy78{eNlAh\|ryP	MWiyNVc4OjB2OR?=
Ly 1	NH3T[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NIL0[mQ1QCCq		NYnLWot4UUN3ME2wMlM1KM7:TR?=	Mm[2NlE4PzJyNEm=
Ly 7	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Mn3IOFghcA>?		M4rvT2lEPTB;MD6wNlUh\|ryP	M1;HRlIyPzd{MES5
Su-DHL6	MnrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVzK[2pGPDhiaB?=		MmjRTWM2OO,:nkKwJO69VQ>?	MXGyNVc4OjB2OR?=
Ly 10	M{SweWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M1jCcVQ5KGh?		NUfmem5oUUN3ME2xMlgh\|ryP	MnnYNlE4PzJyNEm=
RIVA	MkixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2SxWlQ5KGh?		NWTBSXlIUUN3MP-8olIxKM7:TR?=	MmniNlE4PzJyNEm=
Su-DHL2	M1frSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MY[0PEBp		NEDido5KSzVyPUG3MlQh\|ryP	M1vuZlIyPzd{MES5
Ly 1	NHXPTG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M17TVVczKGh?		NWLVZWtLUUN3ME2wMlAyKM7:TR?=	Mn\PNlE4PzJyNEm=
Ly 7	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2\3SFczKGh?		MVHJR\|UxRTBwMEG4JO69VQ>?	NG\Cd\|AzOTd5MkC0PS=>
Su-DHL6	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXi3NkBp		NFTicYxKSzVyPUGuOkDPxE1?	NFmxT\|gzOTd5MkC0PS=>
Ly 10	M1;Tbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVK3NkBp		M4XVR2lEPTB;MT6yJO69VQ>?	NHXBSY4zOTd5MkC0PS=>
RIVA	M2jCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NEC3[lc4OiCq		NGrLcJRKSzVy78{eNlAh\|ryP	M3nUO\|IyPzd{MES5
Su-DHL2	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXW3NkBp		MVzJR\|UxRTFzLkKg{txO	NILyNmkzOTd5MkC0PS=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Survivin / Bcl-2 / p53 / c-Myc / DNMT1; PubMed: 26384351 Oncotarget HL60/ADR and kasumi-1 cells were lysed after treated with 0, 1, 2, 4μM decitabine for 72h, and antibodies against β-actin was used as loading control of whole cell proteins in western blotting. The expression of DNMT1, c-Myc, P53, Bcl-2 and Survivin were determined in AML cells. p-AKT / AKT / p-GSK3β / GSK3β / p-Myc / Myc / p-P70 / P70 / p-4EBP-1 / 4EBP-1 / PTEN; PubMed: 25762617 Oncotarget Effects of decitabine on the expression of survival pathway proteins at the indicated concentrations. phospho-p38 / p38 / phospho-NFκB / NFκB; PubMed: 26617834 Int J Clin Exp Pathol Decitabine suppressed the phosphorylation of p38 and NF-κB. p-JAK1 / JAK1 / p-JAK2 / JAK2 / p-STAT3 / STAT3 ; PubMed: 26692933 Am J Transl Res DAC inhibits the activity of JAK/STAT3 signaling pathway in HL-60 cells. A. HL-60 cells were exposed to 0.2-1.0 μM DAC for 48 h. Cell lysates were prepared and subjected to western blot assay for p-STAT3 (Tyr705 and Ser727) and total STAT3 protein. DAC treatment led to the dephosphorylation of STAT3 both at Tyr705 and Ser727, with moderate effect on total STAT3 protein. B. DAC also down-regulated the expression of p-JAK1 and p-JAK2 as well as total JAK1 and JAK2 in HL-60 cells. The protein expression of STAT3 and JAKs was normalized to that of β-actin and results are representative from three independent experiments. E-cadherin / N-cadherin / Snail / MMP-2 / MMP-9 / Bcl-2 / Bax; PubMed: 28152502 Oncotarget The protein level of EMT and invasion related proteins E-cadherin, N-cadherin, Snail, MMP-2, MMP-9 and the protein level of the apoptotic-related proteins, BCL-2 and Bax were detected by western blot. β-actin served as a internal control.	26384351 25762617 26617834 26692933 28152502
Immunofluorescence	DNMT1; PubMed: 21303982 Cancer Res Ren-01 cells (low passage number RCC cells) at <40% confluence were treated with decitabine 0.5 μM. DNMT1 was quantified 48 hours later by immuno-fluorescence (green dots). DAPI was used to stain nuclei (blue stain). E-cadherin / MMP-9; PubMed: 28152502 Oncotarget Immunofluorescence microscopy to identify invasion-promoting molecule MMP-9 and EMT-protective molecule E-cadherin in YES-2 and TE13 cells treated with DAC.	21303982 28152502
Growth inhibition assay	Cell viability; PubMed: 26384351 Oncotarget Cells were treated with Decitabine for 72 h. Viability was measured by MTT assay in AML cells and patient samples Different AML cells.	26384351

In vivo

In a ALK+ KARPAS-299 murine xenograft model, Decitabine at a dose of 2.5 mg/kg causes increased apoptosis and reduced proliferation of tumor cells, and also results in demethylation of tumor suppressor p16INK4A. ^[2]

Protocol

Kinase Assay:^[1]	- Collapse DNA synthesis assay : The rate of DNA synthesis is measured by the incorporation of radioactive thymidine into DNA. HL-60 and KG1a cells are suspended in 2 mL RPMI medium containing 10% fetal serum in 6-well (35 mm diameter) dishes and incubated with different concentrations of corresponding drugs for 48 hours (drugs are added simultaneously). At 48 hours, 0.5 μCi [³H] thymidine (6.7 Ci/mmol) is added to each well and incubated for an additional 24 hours. The cells are placed on GF/C glass fiber filters (2.4 cm diameter), washed with cold 0.9% NaCl, 5% cold trichloroacetic acid and ethanol. The filters containing the DNA are then dried, placed in EcoLite scintillation liquid (ICN) and the radioactivity measured using Beckman LS 6000IC scintillation counter. The IC50 is defined as the concentration of drug that inhibits 50% of the DNA synthesis of the leukemic cell lines from the dose–response curve.
Cell Research:^[1]	- Collapse Cell lines: HL-60 and KG1a Concentrations: 0-500 nM Incubation Time: 96 hours Method: For the growth inhibition assay, cells in log phase are placed in 5 mL of medium. Different concentrations of Decitabine are added to the medium simultaneously. Cell counts are performed at the indicated times using a model ZM Coulter Counter. The concentration that produces 50% inhibition of growth (IC50) is determined from the growth curves of the drug treated leukemic cell lines. (Only for Reference)
Animal Research:^[2]	- Collapse Animal Models: KARPAS-299 human cells are inoculated subcutaneously into the right and left flanks of the mice. Formulation: Decitabine is dissolved in sterile PBS . Dosages: ≤2.5 mg/kg Administration: Administered via i.p. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	45 mg/mL (197.18 mM)
	Water	10 mg/mL (43.81 mM)
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): water For best results, use promptly after mixing.	10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Decitabine SDF

Molecular Weight	228.21
Formula	C₈H₁₂N₄O₄
CAS No.	2353-33-5
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	Deoxycytidine
Smiles	NC1=NC(=O)N(C=N1)C2CC(O)C(CO)O2

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04086238	Recruiting	Drug: Decitabine	Healthy	EpiDestiny Inc.	October 9 2019	Phase 1
NCT04113616	Recruiting	Drug: KRT-232\|Drug: Cytarabine\|Drug: Decitabine	Acute Myeloid Leukemia (AML)\|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN)	Kartos Therapeutics Inc.	September 25 2019	Phase 1\|Phase 2
NCT03828084	Completed	Drug: Decitabine	Healthy	EpiDestiny Inc.	April 3 2019	Phase 1
NCT03875287	Recruiting	Drug: Decitabine\|Drug: Cedazuridine	Solid Tumor	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|Astex Pharmaceuticals	April 17 2019	Phase 1
NCT03593915	Recruiting	Combination Product: Alvocidib Plus Decitabine	Myelodysplastic Syndromes (MDS)	Tolero Pharmaceuticals Inc.	August 29 2018	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is S1200 a racemic mixture or a monomer?
Answer:
S1200 is R form

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine

Selleck's Decitabine has been cited by 58 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Decitabine SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA Methyltransferase Signaling Pathway Map

Choose Your Country or Region

By Signaling Pathways

By product type

Decitabine

Selleck's Decitabine has been cited by 58 publications

Purity & Quality Control

Choose Selective DNA Methyltransferase Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Decitabine SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Frequently Asked Questions

DNA Methyltransferase Signaling Pathway Map

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)